Monthly Communication Report

Corporation:	Eli Lilly Canada Inc.
Associated registration:	945684-6034-21
Communication date:	2020-04-16
Posted date:	2020-05-14

Designated Public Office Holders who participated in the communication:	Celia Lourenco, Director General, Biologics and Genetic Therapies Directorate Health Products and Food Branch, Health Canada (HC) Greg Loyst, Director General, Policy and Regulatory Strategies Regulatory, Operations and Enforcement Branch, Health Canada (HC) Pierre Sabourin, Assistant Deputy Minister Health Products and Food Branch, Health Canada (HC) Supriya Sharma, Chief Medical Advisor, HC Health Products and Food Branch, Health Canada (HC) Sheryl Groeneweg, Director General Manufacturing and Life Sciences Branch, Industry Sector, Innovation, Science and Economic Development Canada (ISED) Gina Charos, Director General Infectious Disease Prevention and Control Branch, Public Health Agency of Canada (PHAC) Footnote1 J Patrick Stewart, Director General, Therapeutic Products Directorate Health Products and Food Branch, Great Lakes Pilotage Authority Footnote1
Subject Matter of the communication:	Health,  Research and Development
Responsible Officer who filed this communication report:	Rhonda Pacheco
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
Footnote1  Indicates new information that was added through a monthly communications return.